Johnson & Johnson (JNJ) is in talks to buy Protagonist Therapeutics (PTGX), which had a market value of over $4B as of Thursday’s close, The Wall Street Journal’s Lauren Thomas and Ben Dummett report. J&J, which is already working with Protagonist to develop an oral treatment for immune diseases including plaque psoriasis and ulcerative colitis and has the exclusive rights to commercialize the product, already owns nearly 4% of Protagonist’s shares, according to FactSet.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Trump Trade: GoodRx, others in talks with White House to join TrumpRx
- Johnson & Johnson price target raised to $209 from $185 at RBC Capital
- Johnson & Johnson price target raised to $178 from $176 at Morgan Stanley
- GoodRx, others in talks with White House to join TrumpRx, Reuters reports
- Trump Trade: Generics to be excluded from pharma tariff plan